FDA Grants SAB Biotherapeutics’ SAB-176 Expedited Review Status

April 13, 2023

(24/7 MARKET NEWS) – SAB Biotherapeutics (NASDAQ:SABS) is trading higher following a Benzinga report, this morning, that the FDA granted it Fast Track designation for its SAB-176 investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.

SAB Biotherapeutics is trading at $0.6571 +0.273 (+71.08%), on 5.3 million premarket shares.

Its 52-week trading range is $0.3657 to $3.00. It’s trading well above its 2023 trading levels and if it can trade above the $1 level and this morning’s premarket high of $1.11, while maintaining its strong trading volume, it may try to make a run at its November high price.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.